36.62 USD
+1.3 (+3.68%)
36.62 USD
0 (0%)
ChartMill assigns a Buy % Consensus number of 81% to RAPT. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 59.39. This target is 62.17% above the current price.
RAPT was analyzed by 16 analysts. The buy percentage consensus is at 81. So analysts seem to be very confident about RAPT.
In the previous month the buy percentage consensus was at a similar level.
RAPT was analyzed by 16 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-11-12 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-11-07 | Barclays | Maintains | Overweight -> Overweight |
| 2025-11-03 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-10-27 | Guggenheim | Initiate | Buy |
| 2025-10-27 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-10-21 | Clear Street | Maintains | Buy -> Buy |
| 2025-10-21 | Barclays | Maintains | Overweight -> Overweight |
| 2025-10-21 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-10-20 | JP Morgan | Upgrade | Neutral -> Overweight |
| 2025-10-13 | Barclays | Initiate | Overweight |
| 2025-09-30 | Clear Street | Maintains | Buy -> Buy |
| 2025-09-26 | Leerink Partners | Upgrade | Market Perform -> Outperform |
| 2025-08-12 | UBS | Maintains | Neutral -> Neutral |
| 2025-08-08 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-07-30 | JP Morgan | Upgrade | Underweight -> Neutral |
| 2025-07-22 | LifeSci Capital | Initiate | Outperform |
| 2025-07-10 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-05-22 | UBS | Maintains | Neutral -> Neutral |
| 2025-03-10 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-12-26 | HC Wainwright & Co. | Upgrade | Neutral -> Buy |
| 2024-11-25 | HC Wainwright & Co. | Reiterate | Neutral |
| 2024-11-12 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2024-11-12 | HC Wainwright & Co. | Reiterate | Neutral |
| 2024-11-11 | JP Morgan | Downgrade | Neutral -> Underweight |
| 2024-09-09 | UBS | Maintains | Neutral -> Neutral |
| 2024-08-20 | HC Wainwright & Co. | Reiterate | Neutral |
| 2024-07-23 | HC Wainwright & Co. | Reiterate | Neutral |
| 2024-05-14 | Wolfe Research | Downgrade | Outperform -> Peer Perform |
| 2024-05-10 | Guggenheim | Downgrade | Buy -> Neutral |
| 2024-05-10 | Barclays | Downgrade | Overweight -> Equal-Weight |
RAPT THERAPEUTICS INC / RAPT FAQ
Can you provide the average price target for RAPT THERAPEUTICS INC stock?
16 analysts have analysed RAPT and the average price target is 59.39 USD. This implies a price increase of 62.17% is expected in the next year compared to the current price of 36.62.
What is the consensus rating for RAPT stock?
The consensus rating for RAPT THERAPEUTICS INC (RAPT) is 81.25 / 100 . This indicates that analysts generally have a positive outlook on the stock.
How many analysts cover RAPT THERAPEUTICS INC (RAPT) stock?
The number of analysts covering RAPT THERAPEUTICS INC (RAPT) is 16.